"It's the first study to show a significant difference between all three covalent BTK inhibitors," says Daniel A. Ermann, MD.
Pharmaceutical Technology on MSN
Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe
The Jaypirca application moves to the EC for a decision, expected within the next one to two months.
Eli Lilly and Co (NYSE:LLY) shares climbed nearly 6% on Friday after the European Medicines Agency's Committee for Medicinal ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating ...
Detailed price information for Nurix Therapeutics Inc (NRIX-Q) from The Globe and Mail including charting and trades.
Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors. In an interview with Targeted Oncology at the ...
Nurix Therapeutics, Inc. presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing their innovative targeted protein degradation medicines aimed at addressing various cancers, ...
Callie Coombs, MD, and Roy Beveridge, MD, discuss the education needed for payers and physicians surrounding the use of the Bruton tyrosine kinase inhibitors. Ryan Haumschild, PharmD, MS, MBA: Dr ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Anita Kumar, MD: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results